1. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.
2. HRG skews TAM polarization away from the M2- to a tumor-inhibiting M1-like phenotype, promoting antitumor immune responses and vessel normalization.
3. HRG is a promising anticancer drug target that combats malignancy by enhancing immunity and vessel normalization.
The article is generally reliable and trustworthy, as it provides evidence for its claims in the form of data from experiments conducted on human cancer samples, mouse models, and cell lines. The authors also provide detailed explanations of their findings, which are supported by relevant literature citations. However, there are some potential biases in the article that should be noted. For example, the authors do not explore any counterarguments or present both sides equally when discussing the role of HRG in tumor angiogenesis; instead they focus solely on its antiangiogenic effects without considering any potential proangiogenic effects it may have. Additionally, the article does not mention any possible risks associated with using HRG as an anticancer drug target or discuss any potential side effects that may arise from its use. Furthermore, while the authors provide evidence for their claims regarding HRG's ability to inhibit tumor growth and metastasis, they do not provide any evidence for their claim that HRG can improve chemotherapy outcomes; this should be further explored before making such a claim. Finally, there is some promotional content in the article as it emphasizes the potential therapeutic benefits of targeting HRG for anticancer treatment without providing sufficient evidence to support these claims.